iTeos to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 13, 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call and live webcast on May 13, 2021, at 4:30 p.m. ET to discuss its first quarter 2021 financial results and provide a corporate update. The company focuses on developing immuno-oncology therapeutics, with key programs including EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Both candidates are currently undergoing clinical trials to evaluate their effectiveness in treating advanced solid tumors.
- Ongoing Phase 1/2a trials for EOS-448 and inupadenant show promising preliminary results.
- Innovative pipeline targeting validated immuno-oncology pathways.
- None.
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 06, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, May 13th, 2021 to report its first quarter 2021 financial results and provide a corporate update.
Conference Call
Dial-in numbers: (833) 607-1661 (US/Canada) or (914) 987-7874 (International); Conference ID: 6160559
Webcast
A live audio webcast will be accessible from the Events page of the Company’s IR website at https://investors.iteostherapeutics.com/news-and-events/events. A replay will be available on the Company’s website approximately two hours after completion of the event and for 30 days following the call
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of cancer immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1/2a clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity in the dose escalation portion of the trial. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
FAQ
When will iTeos Therapeutics report its Q1 2021 financial results?
What is the focus of iTeos Therapeutics?
What are the key product candidates of iTeos Therapeutics?
What type of clinical trials is iTeos conducting?
